Med. praxi. 2013;10(1):8-11

Fixed combination: a new trend in hypertension management

MUDr.Eva Kociánová, MUDr.Jan Václavík, MUDr.Miloš Táborský
I. interní klinika &ndash, kardiologická, Fakultní nemocnice Olomouc

Due to its prevalence of 20–50 % in the adult population in industrialized countries, hypertension along with diabetes, obesity, hyperlipidaemia,

and smoking is among the major risk factors for cardiovascular mortality. This risk is significantly reduced by achieving target

blood pressure levels with adequate treatment and lifestyle measures. The low proportion of hypertensive patients who achieve these

target levels remains a problem. In the majority of them, it cannot be achieved by using monotherapy, and combination therapy is the

method of choice. Fixed drug combinations are more comfortable for the patient, improve their relationship to long-term treatment,

and are more effective and prognostically more suitable; therefore, they should be considered and preferred in the management of hypertension.

Being acquainted with currently available fixed double combinations and selecting an ideal one to treat a particular patient

with respect to comorbidities has become a new must in the modern management of hypertension.

Keywords: hypertension, combination therapy, fixed combination

Published: January 15, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kociánová E, Václavík J, Táborský M. Fixed combination: a new trend in hypertension management. Med. praxi. 2013;10(1):8-11.
Download citation

References

  1. Filipovský J, Widimský jr. J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2012. Doporučení České společnosti pro hypertenzi. Hypertenze & kardiovaskulární prevence 2012? 3: 1-16.
  2. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States 1988-2000. JAMA. 2003? 298: 199-206. Go to original source... Go to PubMed...
  3. Cífková R, Bruthans J, Adámková V, et al. Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006-2009. Studie Czech post-MONICA. Cor Vasa 2011? 53: 220-229.
  4. Atreja A, Bellam N, Levy S. Strategies to enhance patient adherence: Making it simple. Med-scape General Medicine 2005; 7(1): 4.
  5. Hess G, Hill J, Lau H, et al. Medication Utilization Patterns and Hypertension-Related Expenditures among Patients Who Were Switched from Fixed-Dose To Free-Combination Antihypertensive Therapy. P T 2008; 33: 652-666.
  6. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122(3): 290-300. Go to original source... Go to PubMed...
  7. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-719. Go to original source... Go to PubMed...
  8. Corrao G, Nicotra F, Parodi A, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practise. Hypertension 2011; 58(5): 566-572. Go to original source... Go to PubMed...
  9. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): Lancet 2007; 370: 829-840.
  10. Beckett NS, Peters R, Fletcher AE, et al. For the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898. Go to original source... Go to PubMed...
  11. Yamamuro M, Yamamoto K, Kan H, et al. Effects of a Fixed Combination of Losartan With Hydrochlorothiazide on Glucose Tolerance in Hypertensive Patients Uncontrolled with Angiotensin II Receptor Blockers Alone. J Atheroscler Thromb. 2012 Nov 16.
  12. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regiment of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure LOwering Arm (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet 2005; 366: 895-906. Go to original source... Go to PubMed...
  13. Rothwell P, Howard S, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375(9718): 895-905. Go to original source... Go to PubMed...
  14. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428. Go to original source... Go to PubMed...
  15. Nadar S, Lim HS, Beevers DG, et al. Lipid lowering in hypertension and heart protection: observation from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study. J Hum Hypertens 2002; 16: 815-817. Go to original source... Go to PubMed...
  16. The ONTARGET Investigators Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events, N Engl J Med 2008; 358: 1547-1559. Go to original source... Go to PubMed...
  17. Malacco E. Nebivolol/hydrochlorothiazide (HCTZ) combination in patients with essential hypertension: a pooled analysis from five non-interventional studies with a focus on diabetic and elderly patients. European Review for Medical and Pharmacological Sciences 2010; 14(5): 427-434. Go to PubMed...
  18. Marazzi G, Volterrani M, Caminiti G, et al. Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. Adv Ther 2010; 27(9): 655-664. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.